Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Moody's Affirms Mylan (MYL) at 'Baa3'; Moves Outlook to Developing (TEVA)
April 22, 2015 10:03 AM EDTMoody's Investors Service affirmed the Baa3 senior unsecured rating of Mylan Inc. (subsidiary of Mylan NV, together Mylan (Nasdaq: MYL)) and changed the outlook to developing from stable. The change in outlook reflects heightened event risk and uncertainty around the direction of the ratings given Teva Pharmaceutical Industries Ltd's (Teva, A3 negative, (NYSE: TEVA)) unsolicited offer to acquire Mylan. Teva's offer follows Mylan's unsolicited offer to acquire Perrigo Company plc (Baa3 stable), which Perrigo... More
Teva Pharma (TEVA) Files HSR Notification Regarding Proposed Acquisition of Mylan (MYL)
April 22, 2015 8:33 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Tevas proposal for Mylan implies a total equity value of approximately $43 billion and an... More
